Elevating standards, instilling hope
At Liquidia, we are dedicated to developing best-in-class therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to help patients breathe easier and live longer.
Expertise in pulmonary hypertension
Our proprietary formulations and innovative delivery methods are the result of a team with decades of experience developing drugs to address unmet needs in pulmonary hypertension.
A pipeline of innovation
See how we are working to improve therapeutic benefit for patients.
Engineering the future
Discover how we are using our proprietary PRINT® technology to enhance the efficacy, tolerability, and convenience of medicines for patients with cardiopulmonary disease.
Supporting patients
Our work is driven by the patients we serve. As we continue to advance therapies for cardiopulmonary diseases like PAH and PH-ILD, we encourage patients to explore resources and learn more about our clinical trials.
Join our team
We are steadfast in our commitment to improve outcomes for patients with cardiopulmonary disease. Join our mission to change lives for the better.
